{"entity":{"id":"diffusing-alpha-emitter-radiotherapy","kind":"technology","name":"Diffusing alpha-emitter radiation therapy (Alpha DaRT)","aka":["Alpha DaRT","Diffusing alpha-emitters radiation therapy","Intratumoural diffusing alpha emitters"],"tldr":"Thin metal sources carrying radium-224 are placed inside a solid tumour. As the radium decays, short-lived radioactive atoms leave the source, spread a few millimetres through the tumour and give off alpha particles, a radiation that does heavy damage over a very short distance. The human evidence so far is small studies with no comparison group.","summary":"Alpha particles deposit their energy over less than a tenth of a millimetre, too short a range for a sealed source to treat a tumour. Diffusing alpha-emitter radiation therapy, proposed at Tel Aviv University by Arazi, Kelson, Keisari and colleagues in 2007, gets round this by fixing radium-224 to an implanted source and letting its decay products do the travelling: radon-220, polonium-216 and lead-212 atoms recoil off the surface, disperse in the tissue and deliver dose through their own alpha decays. In mouse squamous cell carcinomas the method produced a necrotic region 5 to 7 mm across around each source, and lead-212 was found to leave the tumour through the blood.\n\nThe first-in-human study (Popovtzer and colleagues, 2020) treated 31 skin and head and neck squamous cell carcinomas in 28 patients, 42% of the lesions previously irradiated. Of 28 lesions assessed, 22 (78.6%) had a complete response and 6 a partial response; 5 of the 22 complete responders relapsed locally at a median of 4.9 months, with a median follow-up of 6.7 months. Acute toxicity was mostly local pain, redness, swelling and mild skin ulceration. In the brain, the REGAIN study in recurrent glioblastoma had treated eight patients by November 2026 (interim, sponsor-reported; see the trial record).\n\nAlpha Tau Medical, the developer, states that Alpha DaRT has marketing approval in Japan for unresectable locally advanced or locally recurrent head and neck cancer and in Israel for squamous cell carcinoma of the skin and oral cavity, and that it is otherwise investigational. No randomised comparison with standard radiotherapy or brachytherapy has been published in the sources read here.","status":"emerging","asOf":"2026-11-18","links":[{"label":"Arazi et al., Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters (Phys Med Biol 2007)","url":"https://doi.org/10.1088/0031-9155/52/16/021"},{"label":"Popovtzer et al., first-in-human trial in skin and head and neck squamous cell carcinoma (Int J Radiat Oncol Biol Phys 2020)","url":"https://doi.org/10.1016/j.ijrobp.2019.10.048"},{"label":"Palmer et al., REGAIN safety interim analysis, abstract CTNI-43 (Neuro-Oncology 2026;28 Suppl 4)","url":"https://doi.org/10.1093/neuonc/noag189.402"},{"label":"Alpha Tau release of 15 November 2026, as filed with the SEC (regulatory status, intracranial delivery)","url":"https://www.sec.gov/Archives/edgar/data/1871321/000121390026120072/ea031236301ex99-1.htm"},{"label":"ClinicalTrials.gov NCT06910306","url":"https://clinicaltrials.gov/study/NCT06910306"}],"tags":["alpha-emitter","device"],"related":[],"cancers":["glioblastoma","head-and-neck"],"sections":["radiation"],"technologies":["brachytherapy","targeted-alpha-therapy"],"targets":[],"drugs":[],"companies":["alpha-tau-medical"],"institutions":["tel-aviv-university"],"pathways":[],"terms":[],"trials":["regain-alpha-dart"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Sources impregnated with radium-224 release radon-220, polonium-216 and lead-212 atoms by recoil; the atoms disperse inside the tumour and deliver a high dose through their alpha decays (Arazi 2007).","strengths":["Uses alpha radiation, which does not depend on oxygen to damage DNA, against solid tumours that a sealed alpha source could not cover","The first-in-human study reported complete responses in 22 of 28 assessed skin and head and neck lesions, 42% of all lesions having been irradiated before","For the brain, sources are placed through a burr hole without open craniotomy (sponsor description)"],"limitations":["Every human result so far comes from a single-arm study; the largest read here treated 28 patients","Each source treats a region a few millimetres across (5 to 7 mm in mouse tumours), so coverage depends on where the sources can be placed","Lead-212 leaves the tumour through the blood (measured in mice), so some activity reaches the rest of the body","In brain that had been irradiated before, follow-up scans showed necrosis or suspected necrosis in four of six assessed patients in the REGAIN interim report"]},"route":"/technologies/diffusing-alpha-emitter-radiotherapy/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"}],"technology":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"company":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/"}],"institution":[{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","route":"/institutions/tel-aviv-university/"}],"trial":[{"id":"regain-alpha-dart","kind":"trial","name":"REGAIN (Alpha DaRT in recurrent glioblastoma)","route":"/trials/regain-alpha-dart/"}]}}